-
Telcagepant, a new oral calcitonin gene-related peptide receptor antagonist, has similar efficacy and better tolerability for acute migraine headaches as compared to a triptan.
-
-
-
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
-
This study from the University of Toronto sought to quantify the number of individual pieces of clinical information entered into the medical record on each patient in the ICU each day.
-
Pulmonary hypertension (ph) is common among patients in the intensive care unit (ICU). In fact, many ICU clinicians simply view PH the same way they view leukocytosis as an expected finding caused by the "bigger problems" of sepsis, respiratory failure, congestive heart failure, volume overload, and myocardial infarction.
-
Despite concerns that recombinant human Activated Protein C (rhAPC) is associated with an increased risk of bleeding, the FDA failed to list several of the bleeding-related exclusion criteria used in the PROWESS trial as contraindications to use of this agent.
-
Post-extubation laryngeal edema, although infrequent, can necessitate reintubation and lead to other complications.